The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
来源
The International Journal of Cardiovascular Imaging | 2019年 / 35卷
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [21] Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy?
    Wallace, N. D.
    Alexander, M.
    Xie, S.
    Ball, D.
    Solomon, B.
    Plumridge, N.
    Shaw, M.
    Harden, S.
    Hegi-Johnson, F.
    Siva, S.
    John, T.
    Officer, A.
    MacManus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S289 - S290
  • [22] CONCURRENT CHEMORADIOTHERAPY FOR PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CARCINOMA; A REAL-LIFE EXPERIENCE
    Yilmaz, Ufuk
    Kirakli, Esra K.
    Polat, Gulru
    Karadogan, Ilker
    Akcay, Cimen
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1152 - S1152
  • [23] Older patients with inoperable non-small cell lung cancer Long-term survival after concurrent chemoradiotherapy
    Semrau, Sabine
    Zettl, Heike
    Hildebrandt, Guido
    Klautke, Gunther
    Fietkau, Rainer
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (12) : 1125 - 1132
  • [24] Pathological Status of Mediastinal Lymph Nodes after Preoperative Concurrent Chemoradiotherapy Determines Prognosis in Patients with Non-Small Cell Lung Cancer
    Shintani, Yasushi
    Funakoshi, Yasunobu
    Inoue, Masayoshi
    Takeuchi, Yukiyasu
    Okumura, Meinoshin
    Maeda, Hajime
    Ohta, Mitsunori
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 18 (06) : 530 - 535
  • [25] Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer
    Miura, S.
    Inoue, K.
    Hontsu, S.
    Tanaka, H.
    Miyauchi, M.
    Asakawa, I.
    Tamamoto, T.
    Hasegawa, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S859 - S860
  • [26] Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy
    Dang, Jun
    Li, Guang
    Zang, Shuang
    Zhang, Shuo
    Yao, Lei
    RADIATION ONCOLOGY, 2014, 9
  • [27] Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum- based chemoradiotherapy - single institute experience
    Vrankar, Martina
    Stanic, Karmen
    Jelercic, Stasa
    Ciric, Eva
    Vodusek, Ana Lina
    But-Hadzic, Jasna
    RADIOLOGY AND ONCOLOGY, 2021, 55 (04) : 482 - 490
  • [28] PROGNOSIS OF STAGE III NON-SMALL CELL LUNG CANCER PATIENTS INITIALLY PRESENTING WITH SUPERIOR VENA CAVA SYNDROME TREATED WITH PARTIALLY ACCELERATED DEFINITIVE CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Pehlivan, Berrin
    Selek, Ugur
    Ozyilkan, Ozgur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1149 - S1149
  • [29] LONG TREATMENT DURATION IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS RECEIVING CONCURRENT CHEMORADIOTHERAPY WITH THE DIAGNOSIS OF STAGE IIIB NON-SMALL CELL LUNG CANCER
    Topkan, Erkan
    Parlak, Cem
    Pehlivan, Berrin
    Ozyilkan, Ozgur
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1150 - S1150
  • [30] Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation
    Isobe, Kazutoshi
    Hata, Yoshinobu
    Sakaguchi, Shinji
    Sato, Fumitomo
    Takahashi, Shoji
    Sato, Keita
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Mitsuda, Aki
    Terahara, Atsuro
    Shibuya, Kazutoshi
    Takagi, Keigo
    Homma, Sakae
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (03) : 260 - 266